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Abstract 
Skeletal muscle wasting occurs as a corollary of numerous physiological conditions, including 
denervation, immobilization, and aging. The E3 ubiquitin ligases MuRF1 and MAFbx are induced 
under nearly all atrophy conditions and are believed to play a key role in protein degradation. Data 
in this thesis provides interesting new evidence that MuRF1 may also act as a transcriptional 
modulator of atrophy-induced genes or atrogenes. The transcriptional regulation of MuRF1 and 
MAFbx were characterized using a reporter gene system and exhibited repressed activity in C2C12 
cells overexpressing MuRF1. Furthermore, ectopic expression of the myogenic regulatory factors 
(MRFs), MyoD and myogenin, caused significant activation of the MuRF1 and MAFbx reporter 
gene constructs, while co-overexpression of MuRF1 with MRFs resulted in reversal of MRF 
induction of reporter gene activity. Interestingly, ectopic expression of a catalytically dead MuRF1 
RING mutant failed to reverse MRF activation of the reporters, suggesting that ubiquitin ligase 
activity may be necessary for MuRF1 transcriptional regulation. To further investigate a potential 
mechanism of MuRF1 regulation of MRF activity, Western blot analysis was performed to analyze 
MRF protein levels in C2C12 cells overexpressing MuRF1 and MuRF1 RING mutant. Cells with 
ectopic MuRF1 or MuRF1 RING mutant showed repressed levels of myogenin. Additionally, cells 
overexpressing MuRF1 and MuRF1 RING mutant treated with MG132 showed only a partial 
rescue of myogenin protein levels. Finally, chromatin immunoprecipitation was performed to 
analyze occupancy of MRFs at the MuRF1 promoter. Overexpression of MRFs resulted in 
increased MuRF1 promoter immunoprecipitation (IP) and amplification, while co-overexpression 
of MuRF1 with MRFs resulted in a reversal of promoter IP and amplification. These findings 
suggest that MuRF1 may regulate MRF transcriptional activity in a non-canonical fashion giving 
insight into a potentially new mechanism by which MuRF1 may act to transcriptionally regulate 
atrophy-induced gene expression. 
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Chapter 1: Overview of the Involvement of MuRF1 in Skeletal Muscle Atrophy 
Skeletal Muscle Atrophy  
Skeletal muscle is a dynamic tissue distinguished by its ability to receive and interpret external 
cues and integrate them into a physiological response. The maintenance of this tissue depends 
partially on a balance between protein synthesis and degradation that is regulated in response to 
the physiological needs of the individual [1]. This balance can often be disrupted due to a myriad 
of physiological conditions, which cause the rate of protein degradation to outpace the rate of 
protein synthesis. This is characterized as muscle atrophy, a loss of proteins that are essential for 
muscle integrity and function [2, 3]. Some conditions that often give rise to skeletal atrophy include 
sarcopenia, cancer, corticosteroid use, joint immobilization, disuse, and denervation [1,4]. While 
skeletal muscle atrophy and many parts of the atrophy pathway have been well characterized, 
numerous elements in the pathway and their roles have been challenging to define. The 
characterization and future treatment of neurogenic muscle atrophy depends on research that will 
provide a better understanding of the molecular events occurring during this process.  
 
The Ubiquitin Proteasome System and the Role of E3 Ubiquitin Ligases 
Protein degradation in muscle atrophy is primarily handled by the 26S ubiquitin proteasome 
system (UPS). This system operates through ATP-dependent mechanisms driving the proteasome 
to degrade damaged or unneeded proteins by hydrolyzing peptide bonds [5]. Proteins destined for 
degradation through the UPS are tagged with a ubiquitin molecule by E3 ubiquitin ligases such as 
Muscle RING Finger-1 (MuRF1).  
E3 ligase-mediated ubiquitination occurs via a covalent modification of a lysine residue on a target 
protein. This process requires a combination of three different enzymes: E1, E2 and E3. The E1 
enzyme is responsible for hydrolyzing an ATP molecule and adding adenylate to a ubiquitin 
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molecule [5, 6]. After this step is completed, the adenylated ubiquitin is transferred to a cysteine 
residue of the E2, called the ubiquitin-conjugating enzyme [5]. Finally, the E3 ubiquitin ligase 
recognizes the protein that needs to undergo degradation and catalytically transfers the ubiquitin 
to the target protein (Figure 1) [5]. The E3 enzyme is the most selective component of this system, 
as it delegates substrate specificity for the UPS [6].  
 
                                                                              
Figure 1.  Schematic of the ubiquitin proteasome system. Protein degradation by the 26S proteasome involves 
collaboration of three enzymes; a ubiquitin activating enzyme (E1), a ubiquitin conjugating enzyme (E2) and a 
ubiquitin ligase (E3) (Adapted from Molineaux 2012). 
  
MuRF1 as a Marker of Skeletal Muscle Atrophy 
Previous research was conducted aiming to identify specific genetic markers expressed at high 
levels under atrophy conditions [4]. Two markers of interest were up-regulated in response to 
atrophic stimuli: the E3 ubiquitin ligases MuRF1 and Muscle Atrophy F-box (MAFbx) [4]. Bodine 
et al. identified MuRF1 and MAFbx in 2001 using differential expression analysis of muscle 
isolated from rats that had been subjected to immobilization, denervation, or hind limb suspension. 
Interestingly, numerous genes showed altered expression under one or two conditions, but only 
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MuRF1 and MAFbx exhibited induction in response to virtually all conditions of atrophy (Figure 
2) [4]. Furthermore, mice lacking MuRF1 or MAFbx expression were resistant to skeletal muscle 
atrophy compared to their wild-type littermates, suggesting that MuRF1 and MAFbx are important 
mediators of muscle wasting [4, 7, 8, 9]. However, the mechanism by which MuRF1 and MAFbx 
regulate atrophy is still not fully understood. In the years since the discovery of these hallmark 
indicators of muscle atrophy very few targets of these E3 ubiquitin ligases have been identified.  
 
Figure 2.  mRNA expression profiles of MuRF1 and MAFbx in Sprague-Dawley rat gastrocnemius muscle 
under muscle atrophy conditions. MuRF1 and MAFbx showed increased expression following limb immobilization, 
sciatic nerve denervation, and hind limb suspension by day 1 with maximum expression reached by 3 days. Numbers 
represent days post-denervation. (Adapted from Bodine, et al., 2001.)  
 
 
MuRF1 is an E3 ubiquitin ligase induced under virtually all atrophy conditions, suggesting that it 
plays a large role in the destabilization of proteins through the UPS during muscle wasting [4, 10, 
11, 12]. MuRF1 has three different functional domains that suggest its potential function(s) in 
muscle atrophy (Figure 3). The Really Interesting New Gene (RING) domain is predicted to 
perform the catalytic action of MuRF1’s participation in ubiquitination and is needed for E3 ligase 
activity [13, 14, 15]. There are also B-box and B-box c-terminal (Bbc) domains that possibly form 
additional zinc finger structures that aid in binding to DNA and/or other proteins [15]. The function 
of the acidic c-terminus of MuRF1 currently has no known function; however, acidic protein 
termini are thought to have a possible role in the subcellular localization of proteins [16].  
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Figure 3. Alignment schematic of the MuRF1 Protein. MuRF1 protein sequences for mouse, rat and human 
were downloaded from the Ensembl database (www.ensembl.org). The sequences were then aligned using the 
Clustal Omega alignment tool (http://www.ebi.ac.uk/Tools/msa/clustalo/) and shaded using the Boxshade tool 
available on the ExPASy Bioinformatics Resource Portal (http://www.expasy.org/).  
 
MuRF1 as a Transcriptional Regulator of Muscle Atrophy 
MuRF1 knock-out (KO) mice were created to better understand the targets of MuRF1 under 
atrophy conditions. A β-galactosidase-encoding lacZ cassette was inserted within the coding 
region of the MuRF1 gene. In theory, MuRF1 wild-type (WT) mice produce functional MuRF1 
gene product while KO mice containing the lacZ cassette produce β-galactosidase under control 
of the MuRF1 endogenous promoter. Microarray analysis was performed on intact and denervated 
gastrocnemius tissue that was isolated from MuRF1 WT and KO mice [13]. MuRF1 gene 
expression increased in WT mice following denervation and decreased back to baseline levels by 
14 days post-denervation. However, in the MuRF1-null mice, levels of β-galactosidase increased 
and remained elevated at 14 days after denervation. The significance of these data lies within the 
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observation that the levels of MuRF1 returned to baseline at two weeks post-denervation, whereas 
the levels of β-galactosidase remained elevated at 14 days post-denervation. Both β-galactosidase 
and MuRF1 are under the control of the same endogenous MuRF1 promoter, thus it is reasonable 
to hypothesize that in wild-type mice MuRF1 may participate in a feedback loop to negatively 
regulate its own transcriptional activity (Figure 4) [13].  
 
  
 
Figure 4. Transcriptional regulation of the MuRF1 gene locus is altered in MuRF1-null mice following 
denervation. Whole genome expression analysis was conducted on gastrocnemius muscle from (A) wild-type (WT) 
and (B) MuRF1-null (KO) mice following 3 days (3D) and 14 days (14D) post-denervation. MuRF1 expression was 
elevated at 3 days post-denervation but returned to baseline expression levels by 14 days post-denervation in WT mice 
(A). In contrast, β-galactosidase, which is inserted into the MuRF1 locus in the MuRF1-null mice and is under the 
control of the endogenous MuRF1 regulatory region, increased at 3 days post-denervation, but remained elevated at 
14 days post-denervation in KO mice (B). Each condition was conducted in triplicate and the expression is the average 
of three individual mice and error reflects +/- SEM. 
 
Data from the microarray also suggests that MuRF1 might be necessary for the transcriptional 
regulation of MAFbx expression under denervation conditions. Expression levels of MAFbx 
showed the same trend that was observed with MuRF1: in WT mice MAFbx expression increased 
after 3 days of denervation but returned to baseline by 14 days post-denervation. However, in the 
MuRF1-KO mice MAFbx expression increased following 3 days of denervation, but also remained 
elevated at 14 days post-denervation (Figure 5).  
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Figure 5. MAFbx expression is altered in MuRF1-null mice following denervation. Whole genome expression 
analysis was conducted on gastrocnemius muscle from (A) wild-type (WT) and (B) MuRF1-null (KO) mice following 
3 days (3D) and 14 days (14D) post-denervation. MAFbx expression was elevated at 3 days post-denervation but 
returned to baseline expression levels by 14 days post-denervation in WT mice (A). In contrast, MAFbx expression 
increased at 3 days post-denervation, but remained elevated at 14 days post-denervation in KO mice (B). Each 
condition was conducted in triplicate and the expression is the average of three individual mice and error reflects +/- 
SEM.  
 
As previously mentioned, very few targets of MuRF1 have been identified despite its establishment 
as an E3 ubiquitin ligase. Interestingly, outside of this function E3 ligases have been characterized 
to be capable of mono-ubiquitination and multi-ubiquitination [17]. These ubiquitination events 
do not flag proteins for degradation by the 26S proteasome but instead change the protein’s 
structure, cellular localization, function, or serves as a recruitment or binding signal for additional 
transcription factors [17]. It is hypothesized that MuRF1 may function to transcriptionally regulate 
gene expression in skeletal muscle through ubiquitination events resulting in the ability to 
coordinate with myogenic regulatory factors to control gene activity. The ability of MuRF1 to act 
as a transcriptional regulator would demonstrate that E3 ligases such as MuRF1 may have a larger 
role in atrophy than previously thought. 
 
Myogenic Regulatory Factors 
 
Myogenic regulatory factors (MRFs) are crucial to stimulating and regulating the formation of 
muscle tissue (Figure 6). These transcription factors act in conjunction with co-activators or co-
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repressors to facilitate transcription of muscle-specific genes. MRFs are characterized by a 
standard helix-loop-helix motif, which allows them to bind to the canonical Ebox consensus 
sequence of 5’-CANNTG-3’ [18]. These Ebox sequences are found in the promoter regions of 
most muscle-specific genes, including MuRF1 and MAFbx, and function as binding sites for 
MRFs to modulate transcriptional activity. MyoD and myogenin sequentially and transitorily 
associate with promoter regions of a variety of muscle-specific genes. These factors are necessary 
for the development of functional skeletal muscle and myogenic commitment, respectively [4, 5, 
19].  
 
 
Figure 6. Model of skeletal muscle myogenesis. The growth of uncommitted mesodermal cells into committed 
myotubes depends on cellular signaling from transcription factors including Pax3, Pax7, MyoD1, and Myogenin. 
MyoD1 aids in the commitment from satellite cells to un-differentiated muscle myoblast cells whereas myogenin 
functions to regulate the formation of differentiated myotubes (Image adapted from Hettmer and Wagers, 2010). 
 
The microarray data demonstrated that MuRF1 also has a role in regulating the transcription of the 
myogenic regulatory factors myogenin and MyoD, which are often upregulated in atrophy 
conditions [13]. Microarray analysis showed that myogenin and MyoD are significantly 
upregulated under denervation. The expression levels of MyoD in MuRF1-KO mice showed 
decreased levels at 14 days post-denervation compared to WT mice, whereas expression of 
myogenin showed a significant decrease at 3 days post-denervation in MuRF1-KO mice compared 
to WT mice (Figure 7). These data together further suggest that MuRF1 may act as a regulator of 
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muscle-specific genes and that myogenin and MyoD may play a role in the atrophy pathway 
involving MuRF1.    
 
 
Figure 7.  MRF expression is altered in MuRF1-null mice following denervation. Whole genome expression 
analysis was conducted on gastrocnemius muscle from wild-type (WT) and MuRF1-null (KO) mice following 3 days 
(3D) and 14 days (14D) post-denervation. A) MyoD1 and B) myogenin expression increased at both 3 and 14 days 
following denervation in wild-type and MuRF1-null mice. Each condition was conducted in triplicate and the 
expression is the average of three individual mice and error reflects +/- SEM. 
 
Myogenin is established as an agent of myoblast commitment to differentiation and is required for 
cell viability to ensure the proper formation of embryonic myofibers [18, 20, 21, 22]. Interestingly, 
it was previously found that the deletion of myogenin resulted in diminished expression of MuRF1 
in skeletal muscle and that when these mice experienced neurogenic atrophy (i.e. denervation) 
were resistant to muscle wasting [18]. MyoD acts as an early marker of myogenic commitment to 
the skeletal muscle lineage [18]. Furthermore, MyoD and myogenin have been characterized as 
important regulators of neurogenic atrophy-induced gene expression, including induction of 
MuRF1 and MAFbx [10, 16].  
 
 
A B 
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Myogenic Regulatory Factors as Regulators of MuRF1 and MAFbx 
The transcriptional regulation of MuRF1 and MAFbx by MRFs has been investigated in previous 
unpublished literature which shows that these transcription factors act as co-activators or co-
repressors to mediate transcription of muscle-specific genes [23,24].  Again, the proximal 
promoters of both MuRF1 and MAFbx contain canonical E-box sequences which are known 
binding sites of MRFs (Figure 8, Figure 9) [25].  These conserved E-box sequences have been 
characterized to interact with myogenic regulatory factors, specifically including MyoD and 
myogenin [26].  It is proposed that these muscle specific factors are working cooperatively with 
MuRF1 through conserved Ebox sequences in the promoter region of atrophy-related genes to 
suppress or activate expression under neurogenic atrophy conditions. 
 
 
Figure 8. MAFbx Promoter Alignment. Promoter sequences from mouse, rat, and human MAFbx genes (5000 base 
pairs upstream of the transcription start site (+1) through the first exon) were downloaded from the Ensembl database 
(www.ensembl.org) and aligned using the ClustalW algorithm. Identical sequences for the indicated regions are 
highlighted in black. Approximate positions of potential MRF transcription factor binding sites are circled in the 
alignment: O class, or FoxO, Forkhead binding site (G/A)TAAA(T/C)AA  (Ovals); C/EBP TT(G/T)NGNAA 
(Diamonds); Muscle specific E box CANNTG (MyoD, etc.)  (Large circle). 
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Figure 9. MuRF1 Promoter Alignment. Promoter sequences from mouse, rat, and human MuRF1 genes (5000 base 
pairs upstream of the transcription start site (+1) through the first exon) were downloaded from the Ensembl database 
(www.ensembl.org) and aligned using the ClustalW algorithm. Identical sequences for the indicated regions are 
highlighted in black. Approximate positions of potential transcription factor binding sites are indicated in the 
schematics and highlighted in the alignments: FoxO, (G/A)TAAA(T/C)AA Ovals); C/EBP TT(G/T)NGNAA 
(Diamonds); GRE (Square); Muscle specific E box CANNTG (MyoD, etc.)  (Large Circles). 
 
Previous Characterization of MuRF1 and Myogenic Regulatory Factors in Transcriptional 
Regulation: MuRF1 as a Transcriptional Regulator of MuRF1 and MAFbx 
Previous unpublished data showed the role of MuRF1 and the MRFs in the transcriptional 
regulation of atrogenes.  It was demonstrated that MuRF1 acts, at least in part, by direct and/or 
indirect modulation of the MyoD-family of myogenic regulatory factors. The transcriptional 
activation of MuRF1 and MAFbx by myogenin and MyoD was confirmed and for the first time it 
was demonstrated that MuRF1 cooperates with both MyoD and myogenin to repress MuRF1 and 
MAFbx reporter gene expression (Figures 10 and 11, respectively) [23].  These findings provide 
support for the microarray data showing that both MAFbx and MuRF1 expression remain elevated 
in MuRF1-null mice, suggesting that the MuRF1 gene product is necessary for returning 
expression to baseline levels following neurogenic atrophy. These findings also suggest that 
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MuRF1 may act as a modulator of myogenic regulatory factors, although the exact mechanism has 
been unclear.  
 
 
 
 
Figure 10. MuRF1 negatively regulates MRF induction of MuRF1 promoter reporter activity. The MuRF1 500 
base pair promoter reporter shows transcriptional repression in response to co-overexpression of MuRF1 and (A) 
MyoD or (B) myogenin. C2C12 myoblasts were transfected with a reporter construct consisting of the MuRF1-500bp 
promoter cloned into the SEAP2-Basic plasmid, a β-galactosidase expression plasmid, and expression plasmids for 
MuRF1 alone or in combination with myogenin or MyoD. The myoblasts were maintained in standard differentiating 
culture media. Samples of media were taken at 24 hour intervals and measured for SEAP activity. The samples were 
normalized to β-galactosidase activity to correct for variation in transfection efficiency. Each condition was done in 
triplicate and the error bars represent standard deviation (-/+ S.D.) of the mean [23]. 
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Figure 11. MuRF1 negatively regulates MRF induction of MAFbx promoter reporter activity. The MAFbx 500 
base pair promoter reporter shows transcriptional repression in response to co-overexpression of MuRF1 and (A) 
MyoD and (B) myogenin. C2C12 myoblasts were transfected with a reporter construct consisting of the MAFbx-500bp 
promoter cloned into the SEAP2-Basic plasmid, a β-galactosidase expression plasmid, and expression plasmids for 
MuRF1 alone or in combination with MyoD or myogenin. The myoblasts were maintained in standard differentiating 
culture media. Samples of media were taken at 24 hour intervals and measured for SEAP activity. The samples were 
normalized to β-galactosidase activity to correct for variation in transfection efficiency. Each condition was done in 
triplicate and the error bars represent standard deviation (-/+ S.D.) of the mean [23]. 
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Overview  
MuRF1 and MAFbx are widely accepted as key regulators in skeletal muscle dynamics with roles 
in targeting proteins for degradation. Increasing evidence, including data herein, suggests that 
MuRF1 functions as a transcriptional regulator of muscle-specific gene. The details of MuRF1 and 
its role as a transcriptional regulator of downstream genes has not been thoroughly investigated to 
date.  The purpose of this research was to build on preliminary data aiming to analyze the 
mechanism by which MuRF1 acts as a transcriptional regulator, specifically aiming to characterize 
the coordination of MuRF1 and the myogenic regulatory factors, myogenin and MyoD. The data 
herein suggests that MuRF1 regulates an array of atrogenes by indirect/direct modification and 
interaction with transcription factors such as myogenin and MyoD through the binding of the 
canonical Ebox sequences found in the promoter regions of atrophy-induced genes such as MuRF1 
and MAFbx. The first aim of this thesis was to investigate the regulation of myogenin and MyoD 
by MuRF1. We hypothesize that MuRF1 may be acting as a regulator of myogenin and MyoD by 
one of two mechanisms. One possible way this may be occurring is at the post-translational level, 
through the 26S proteasome; MuRF1 may be acting as an E3 ligase to ubiquitinate the MRFs and 
degrade them through the ubiquitin proteasome system (Figure 12). An alternative mechanism is 
that MuRF1 may also be acting through a feedback mechanism that targets the transcriptional 
activation of the MRFs (Figure 13).  We hypothesize that MuRF1 may be negatively regulating 
levels of MyoD and myogenin. A decrease in expression of myogenin and MyoD may cause 
differential expression of many muscle specific genes, as they are necessary regulatory factors for 
muscle-specific gene expression. 
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Figure 12.  Proteasome Model: MuRF1 regulates myogenin and MyoD through the 26S proteasome. 
MuRF1 acts as an E3 ligase to poly-ubiquitinate myogenin and MyoD and flag them for degradation by the 
ubiquitin proteasome system, down regulating their expression levels and in turn differentially regulating 
the transcription of muscle-specific genes in neurogenic atrophy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13.  Transcription Model: MuRF1 transcriptionally regulates myogenin and MyoD 
expression. MuRF1 may feedback to negatively regulate the transcriptional activity of myogenin or MyoD. 
Transcriptional regulation of atrophy-related genes may be occurring through a) negative regulation of 
MyoD b) negative regulation of myogenin (possibly through modification of MyoD, a known 
transcriptional regulator of myogenin). 
 
B A 
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The second aim of this thesis was to investigate the mechanism by which MuRF1 is coordinating 
with the MRFs, specifically investigating the occupancy of the MuRF1 promoter region by 
myogenin and MyoD. We hypothesized that the MRFs are occupying the Ebox binding domain of 
the MuRF1 promoter at high levels under neurogenic atrophy conditions (i.e. high expression 
levels of the MRFs and MuRF1). We also hypothesized that co-overexpressing MuRF1 with the 
MRFs would result in MuRF1-medicated reversal of this occupancy, based on previously research 
suggesting that MuRF1 is able to transcriptionally regulate its own activity [23]. The data herein 
serves to characterize MuRF1 as a transcriptional regulator of atrophy induced genes through the 
regulation of myogenin and MyoD in addition to characterizing the molecular mechanism by 
which this is occurring.  
 
Chapter 2: Characterization of the Molecular Interaction between MRFs and MuRF1 
Experimental Design  
 
 
Endogenous expression of myogenin and MyoD 
 
The first objective of this research was to effectively identify and characterize the endogenous 
expression of both myogenin and MyoD in skeletal muscle cells. C2C12 myoblast cells were plated 
and harvested at day 1 (U1) and day 2 (U2) of proliferation and differentiation day 1 (D1), 
differentiation day 3 (D3), differentiation day 7 (D7) and differentiation day 9 (D9). These time 
points were chosen to be representative of the differentiation process of C2C12 mouse myoblast 
cells. The protein was extracted and Western blot analysis was performed to analyze protein levels 
over the time course using antibodies against myogenin or MyoD.  
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MuRF1 regulation of myogenin and MyoD 
 
The next objective was to explore if MuRF1 has a role in regulating the expression levels of 
myogenin and MyoD and how this is occurring. We hypothesized that this regulation may be 
occurring post-translationally, through the ability of MuRF1 to catalytically tag proteins with 
ubiquitin molecules, in turn tagging them for degradation by the proteasome. The role of both the 
catalytic RING domain, which is responsible for ubiquitinating proteins, and the 26S proteasome 
were investigated as follows:  
Role of the Catalytic RING Domain  
In order to analyze the catalytic activity of MuRF1, site directed mutagenesis was performed to 
create a catalytically dead MuRF1 construct. In theory, this MuRF1 RING mutant is unable to 
ubiquitinate proteins and flag them for degradation by the 26S proteasome. C2C12 cells were 
transfected with ectopic MuRF1 or MuRF1-RING mutant and harvested at differentiation day 2 
(D2) and differentiation day 9 (D9). Western blot analysis was performed using antibodies against 
myogenin and MyoD. 
Role of the 26S Proteasome  
 
To evaluate the role of the 26S proteasome in this regulation, C2C12 cells were transfected with 
MuRF1 and then harvested at differentiation day 2 (D2) and differentiation day 9 (D9).  Four hours 
prior to harvesting the cells, the cells were treated with MG132 [12.5µg/µL], a general 26S 
proteasome inhibitor that acts as a peptide aldehyde to effectively block the proteolytic activity of 
the proteasome complex. Subsequently, proteins were extracted, purified and Western blot 
analysis was performed using antibodies against myogenin and MyoD.  
 
 
 
 
17 
 
MuRF1 promoter occupancy by myogenin and MyoD 
 
MuRF1 promoter occupancy by endogenous myogenin and MyoD 
To further characterize MuRF1 regulation of the myogenic regulatory factors, Chromatin 
Immunoprecipitation (ChIP) was performed to analyze the occupancy of myogenin and MyoD at 
the proximal promoter of MuRF1. C2C12 cells were harvested at proliferation day 2 (PD2), 
differentiation day 2 (DD2), and differentiation day 9 (DD9). Chromatin immunoprecipitation was 
performed using antibodies to isolate myogenin or MyoD. DNA was isolated from the protein 
complexes and primers amplifying the conserved Ebox region of the MuRF1 promoter were used 
in qPCR, allowing us to quantify myogenin or MyoD occupation of the Ebox enhancer sequence 
in the promoter region of MuRF1. 
Overexpression of MRFs 
An additional experiment was performed to analyze the amount of association between the MuRF1 
Ebox and MRFs when myogenin and MyoD were overexpressed in the cell line, which mimics 
their expression in neurogenic atrophy. C2C12 cells were transfected to overexpress myogenin or 
MyoD and were harvested at 24 hours post-transfection. Chromatin immunoprecipitation was 
performed using antibodies to pull down myogenin or MyoD. DNA was isolated from the protein 
complexes and primers amplifying the conserved Ebox regions of the MuRF1 promoter were used 
in qPCR, allowing us to quantify myogenin or MyoD occupation of the Ebox enhancer sequence 
in the promoter region of MuRF1. 
Overexpression of MuRF1 + MRFs 
The next aim of this research was to assess the ability of MuRF1 to drive down myogenin and/or 
MyoD occupancy of the MuRF1 proximal promoter. C2C12 cells overexpressing myogenin or 
MyoD +/- MuRF1 were harvested at 24 hours post-transfection, again mimicking expression levels 
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that are seen under neurogenic atrophy. Chromatin immunoprecipitation was performed using 
antibodies to pull down myogenin or MyoD. DNA was isolated from the protein complexes and 
primers amplifying the conserved Ebox regions of the MuRF1 promoter were used in qPCR, 
allowing us to quantify myogenin or MyoD occupation of the Ebox enhancer sequence in the 
promoter region of MuRF1. 
 
Materials and Methods 
 
Cell Culture 
C2C12 mouse myoblast cells were obtained from the American Type Culture Collection (Manassas, 
VA). The cells were grown in 10 cm cell culture dishes in 10 mL of media consisting of DMEM 
(Life Technologies, Grand Island, NY) supplemented with 10% FBS (GE Healthcare Hyclone 
Laboratories, Logan, UT), Pen/Strep, nonessential amino acids, and gentamycin (Life 
Technologies, Grand Island, NY) at 37°C in a 6% CO2 humidified chamber. 
 
Protein Purification and Western Blotting 
 
C2C12 mouse myoblast cells were plated into 10 cm culture dishes at a density of approximately 
500,000 cells/mL Cells were harvested over a time course of 12 days, from proliferating myoblasts 
to differentiated myotubes. Cells being transfected to ectopically express MuRF1 or MuRF1-
RING mutant were treated as follows: one hour prior to transfection the media was removed from 
the cells and 10 mL of fresh proliferation media was added to each plate. 10µg of total DNA per 
plate was transiently transfected using Thermo Scientific Turbofect reagent per the manufacturer’s 
protocol. The DNA mixture consisted of a total of 10ug of indicated expressions constructs for 
pcDNA3.1-MuRF1 or pcDNA3.1-MuRF1 RING mutant. At approximately 24 hours post-
transfection the cells were harvested, centrifuged at 5,000 x g for 5 minutes at 4°C, and stored at -
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80˚C. Protein homogenates were prepared by resuspending the cells in a protein lysis buffer [50 
mM Tris, 150 mM NaCl, 50 mM NaF, .5% NP-40] supplemented with a protease inhibitor 
cocktail, 1 mM PMSF, 1 mM DTT, 10mM β-glycarophosphate, 1mM Sodium Molybdate, 
incubated for 30 minutes on ice and centrifuged at 4°C for five minutes at 18,000 x g. The 
homogenate was aliquoted and stored at -80˚C.  Protein concentrations were quantified using a 
modified Bradford reagent protein assay according to manufacturer’s protocol (Bio-Rad, Hercules, 
CA). A total of 150µg of protein was loaded onto an SDS-PAGE gel, separated and then 
transferred to a PVDF membrane. The membrane was Ponceau-S stained to check for consistent 
protein loading and efficient transfer, washed, and then blocked for one hour in a 5% milk solution 
(5% dry milk weight/volume dissolved in .05% Tween-20 in Tris Buffered Saline). The membrane 
was washed for fifteen minutes with 1x TTBS and incubated in commercially available primary 
antibodies for one hour at room temperature (RT) (MyoD [M-318, rabbit, Santa Cruz 
Biotechnology, Inc. or 5.8A, mouse, Santa Cruz Biotechnology, Inc.]; myogenin [F5D, mouse, 
Santa Cruz Biotechnology, Inc.]; at a concentration of 1:500 myogenin, MyoD. The membranes 
were washed for fifteen minutes, and then incubated in secondary antibody (1:5000) for one hour. 
Signal development followed the manufacturer’s protocol for the Pierce ECL Western Blotting 
Kit and the blots were imaged on x-ray film.  
 
Site-Directed Mutagenesis of MuRF1-RING Finger Domain 
The MuRF1 cDNA sequences for mouse, rat and human were downloaded from the Ensembl 
database (www.ensembl.org). The sequences were then aligned using the Clustal Omega 
alignment tool (http://www.ebi.ac.uk/Tools/msa/clustalo/). The aligned sequences were used to 
identify conserved amino acids for site-directed mutagenesis. Site-directed mutagenesis reactions 
 
20 
 
were performed per the manufacture’s protocol (Stratagene, La Jolla, CA). Mutations in the RING 
domain of the MuRF1 gene were accomplished by using the following primers: (F) 5ʹ-
CTACAGCAACCGTGAGAAGGCCGACTCCAACCACAACC-3ʹ and (R) 5ʹ-
GGTTGTGTTGGAGTCGGCCTTCTCACGGTTGCTGTAG-3ʹ. The resulting MuRF1 clone 
was sequenced to confirm the correct mutation was introduced into the gene.  
 
Chromatin Immunoprecipitation   
C2C12 cells were plated into 10 cm culture dishes at a density of approximately 500,000 cells/mL 
and grown to approximately 75% confluency. One hour prior to transfection the media was 
removed from the cells and 10 mL of fresh proliferation media was added to each plate. Total 
DNA (10µg per well) was transiently transfected using Thermo Scientific Turbofect reagent per 
the manufacturer’s protocol. The DNA mixture consisted of a total of 10ug of indicated expression 
constructs for pcDNA3.1-MuRF1, pcDNA3.1-TCF3, pcDNA3.1-TCF12, pcDNA3.1-MyoD, and 
pcDNA3.1-Myogenin. Each plate was treated with 1% formaldehyde and incubated at 37˚ for ten 
minutes. The cells were treated with .125M glycine, incubated for five minutes, and washed with 
PBS containing protease inhibitor cocktail, 10mM β-glycerophosphate, and 0.5 M Na3VO4. Cells 
were harvested in 1 ml Collection Buffer (10 mM Tris pH 8.0, 150 mM NaCl, 1 mM EDTA), spun 
down at 4°C for five minutes at 3,000 x g, and stored at -80˚C. Cells were resuspended in 400µl 
lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.0, PIC, 10 mM β-glycerophosphate, 
1 mM Na3VO4). The cell lysates were sonicated using a QSonica Ultrasonic Liquid Processor at 
the following optimized settings: 50% amplification; pulses of 20 seconds on, 20 seconds off x 30 
cycles. The samples underwent centrifugation at full speed for 10 minutes and supernatant was 
removed and diluted to 10 mL with ChIP Dilution Solution (0.01% SDS, 1.1% Triton X-100, 1.2 
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mM EDTA, 16.7 mM Tris-HCl, pH 8.0, 167 mM NaCl, PIC, 10 mM β-glycerophosphate, 1 mM 
Na3VO4). The chromatin was pre-cleared using 60µl of a slurry of salmon sperm DNA/protein A 
agarose (Millipore, Temicula, CA) and rotated for 30 minutes at 4°C, beads were then pelleted by 
centrifugation for 2 minutes x 1000g at 4°C. The chromatin was combined with 1 µl of ChIP-grade 
antibody (c-myc [9E10, mouse, Santa Cruz Biotechnology, Inc.], myogenin [F5D, mouse, Santa 
Cruz Biotechnology, Inc.], MyoD [5.8A, mouse, Santa Cruz Biotechnology]) and incubated 
overnight with rotation at 4°C. The samples were combined with 50µl of washed 50% slurry of 
Dilution Solution and Protein A/salmon sperm and incubated with tumbling at 4°C for two hours, 
followed by centrifugation at 10,000 x g for 2 minutes. The beads were then washed 3x with 1 mL 
of each of the following buffers: TSEI (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-
HCl, pH 8.0, 150 mM NaCl), TSEII (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-
HCl, pH 8.0, 500 mM NaCl), TSEIII (1 mM EDTA, 10 mM Tris-HCl, pH 8.0, 1% NP-40, 1% 
sodium deoxycholate, 0.25 M LiCl), Wash Buffer IV (10 mM Tris [pH 8.0], 1 mM EDTA). The 
beads were pelleted by centrifugation at 3,000 x g for 2 minutes, followed by addition of 100µl 
10% Chelex and incubation at 95°C for ten minutes to reverse DNA-protein crosslinks. After 
incubation, the samples were treated with 2µl Proteinase K (Qiagen Sciences, MD) and incubated 
at 55°C for 30 minutes, followed by incubation at 95°C for ten minutes. The samples were 
centrifuged at full speed for two minutes and the supernatant was collected. The remaining beads 
were combined with 100 µl nuclease free water, vortexed, and centrifuged for 2 minutes a full 
speed. The resulting supernatant was collected and combined with respective supernatant from the 
previous step. The collected DNA aliquots were used for qPCR analysis. 
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qPCR 
The qPCR reaction was prepared using 2 µL of chromatin from the ChIP assay, 1 µL of forward 
primer (500nM), 1 µL of reverse primer (500nM), 5 µL iTaq Universal SYBR Green Supermix 
(BioRad) in a total volume of 10 µL. The PCR reaction was cycled at the following parameters: 
95˚C for two minutes, 95˚C for thirty seconds, 57˚C  for thirty seconds, and 72˚C for one minute 
x 40 cycles. The primer sequences used to amplify the MuRF1 promoter were: forward ProEbox 
5’-CGGCAGGGCAACAGCGATTT-3’, reverse ProEbox 5’- GTCTTGGTCTGAGGCCCCTC-
3’. These qPCR reactions were quantified by using a standard curve of amplification of serial 
dilutions of the MuRF1 promoter plasmid at 1,000 pM, 100 pM, and 10 pM in concentration. Each 
condition was performed in triplicate and standard deviation was calculated. 
 
Bioinformatics Analysis  
The nucleotide sequence corresponding to the regulatory regions of mouse, rat, and human MuRF1 
and MAFbx promoters were downloaded from the Ensembl database (www.ensembl.org), aligned 
using ClustalW2 alignment tool on the EMBL website 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/), and shaded using Boxshade analysis of the 
ClustalW2 alignment output data (http://www.ch.embnet.org/software/BOX_form.html). The 
amino acid sequences for mouse, rat, and human MuRF1 were downloaded from Ensembl and 
aligned and shaded as described above. 
 
 
 
 
 
23 
 
← MyoD 
Results   
Characterization of the ectopic expression of myogenin and MyoD in C2C12 myoblasts  
To effectively characterize the endogenous expression of both MyoD and myogenin in skeletal 
muscle cells, C2C12 cells and Western blot analysis was performed to analyze protein levels over 
the course of differentiation. MyoD showed an increase in expression by day 2 of proliferation 
and decreased in expression by day 7 of differentiation (Figure 14). Myogenin increased by day 
3 of differentiation and decreased in expressed late in differentiation (Figure 15).  
  
 
Figure 14. Protein expression profile of MyoD (~45 kDa) in C2C12 mouse myoblasts increases in expression late 
in proliferation and decreases early in differentiation. C2C12 myoblast cells were plated and harvested at day 1 
(U1) and day 2 (U2) of proliferation and day 1 (D1), day 3 (D3), days 7 (D7) and day 9 (D9) after the switch to 
differentiation media (2% serum). Western blotting was performed using 150µg of total protein and probed using an 
antibody against MyoD. 
 
   
 
 
Figure 15. Protein expression profile of myogenin (~34 kDa) in C2C12 mouse myoblasts increases in expression 
early in differentiation and decreases late in differentiation.  C2C12 myoblast cells were plated and harvested at 
day 1 (U1) and day 2 (U2) of proliferation and day 1 (D1), day 3 (D3), days 7 (D7) and day 9 (D9) after the switch to 
differentiation media (2% serum). Western blotting was performed using 150µg of total protein and probed using an 
antibody against MyoD. 
 
 
Ectopic expression of MuRF1 and MuRF1-RING mutant downregulates myogenin but not MyoD 
in C2C12 myoblasts 
To explore if MuRF1 had a role in regulating the expression levels of myogenin and MyoD, 
Western blot analysis was performed on C2C12 mouse myoblasts overexpressing MuRF1 or the 
            U1       U2      D1      D3      D5      D7     D10 
            U1      U2     D1     D3        D5      D7      D10 
← myogenin 
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catalytically dead MuRF1 RING mutant at two time points of differentiation. Western blot 
analysis showed decreased myogenin expression when MuRF1 or MuRF1-RING mutant were 
overexpressed (Figure 16).  Western blot analysis probing for MyoD did not show differences in 
expression when MuRF1 or MuRF1-RING mutant were overexpressed (Figure 17). 
 
 
 
 
 
 
Figure 16. Protein expression profile of myogenin (~34 kDa) in C2C12 mouse myoblasts is decreased upon 
overexpression of MuRF1 or MuRF1-RING mutant. C2C12 myoblast cells were transfected with control expression 
plasmid alone (-/-) or expression plasmids for either MuRF1 or MuRF1 RING mutant and harvested at day 2 (D2) and 
day 9 (D9) after the switch to differentiation media (2% serum). Western blotting was performed using 150µg of total 
protein and probed using an antibody against myogenin (biological duplicate shown Figure S1). 
 
 
 
 
 
 
Figure 17. Protein expression profile of MyoD (~45 kDa) in C2C12 mouse myoblasts remains unaltered upon 
overexpression of MuRF1 or MuRF1-RING mutant. C2C12 myoblast cells were transfected with control 
expression plasmid alone (-/-) or expression plasmids for either MuRF1 or MuRF1 RING mutant and harvested at day 
2 (D2) and day 9 (D9) after the switch to differentiation media (2% serum). Western blotting was performed using 
150µg of total protein and probed using an antibody against MyoD (biological duplicate shown figure S2).  
 
Inhibition of the 26S proteasome blunts MuRF1-mediated downregulation of myogenin  
To evaluate how the role of the 26S proteasome in MuRF1 regulation of myogenin and MyoD, 
C2C12 cells overexpressing MuRF1 were treated with MG132 [12.5µg/µL], a general 26S 
← MyoD 
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proteasome inhibitor [27]. Western blot analysis showed partially increased levels of myogenin 
and MyoD in MG132 treated cells, however ectopic MuRF1 was still capable of blunting the 
expression levels of myogenin without the function of the 26S proteasome (Figure 18, 19).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18.  Protein expression profile of myogenin (~34kDa) in C2C12 mouse myoblasts is increased upon cell 
treatment with MG132 (12.5µg/µL) but is still blunted by ectopic MuRF1. MuRF1-mediated repression of 
myogenin expression levels are partially reversed in the presence of MG132 but are not completely rescued from the 
blunting effect by ectopic MuRF1. Myoblasts were transfected with control expression plasmid alone (-/-) or an 
expression plasmid for MuRF1 and harvested at day 2 (D2) and day 9 (D9) after the switch to differentiation media 
(2% serum). Western blotting was performed using 150µg of total protein probed using an antibody against myogenin 
(biological duplicate shown Figure S3).  
 
 
 
 
 
 
 
Figure 19.  Protein expression profile of MyoD (~45kDa) in C2C12 mouse myoblasts is increased upon cell 
treatment with MG132 (12.5µg/µL). MyoD expression levels are partially reversed in the presence of MG132, but 
no differences are seen upon expression of ectopic MuRF1. Myoblasts were transfected with control expression 
plasmid alone (-/-) or an expression plasmid for MuRF1 and harvested at day 2 (D2) and day 9 (D9) after the switch 
to differentiation media (2% serum). Western blotting was performed using 150µg of total protein probed using an 
antibody against MyoD (biological duplicate shown Figure S3). 
 
 
← MyoD 
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Myogenic regulatory factors bind to the proximal promoter regions of MuRF1 and MAFbx 
Previously, reporter assays showed that MuRF1 coordinates with myogenin and MyoD to 
regulate the promoter activity of atrophy-related genes, such as MuRF1 and MAFbx. Chromatin 
immunoprecipitation was performed to analyze the occupancy of endogenous myogenin and 
MyoD at the proximal promoter of MuRF1. Endogenous MuRF1 promoter binding appeared to 
be highest for myogenin early in differentiation, while MuRF1 promoter binding for MyoD 
appeared to be highest early in proliferation and did not show much of a response late in 
differentiation (Figure 20).  
 
Figure 20.  Endogenous myogenin and MyoD occupy the MuRF1 Ebox promoter region.  The MuRF1 Ebox 
promoter is highly occupied by myogenin early in differentiation (DD2) and by MyoD early in proliferation (PD2). 
C2C12 myoblast cells were harvested at day 2 post-plating (PD2) and day 2 (DD2) and day 5 (DD5) after the switch 
to differentiation media (2% serum). The myoblasts were maintained in standard culture media. ChIP was performed 
and DNA-protein complexes were pulled down with antibodies for myogenin (anti-myogenin) and MyoD (anti-
MyoD). Each qPCR condition was run in triplicate and the error bars represent standard deviation (-/+ S.D.) of the 
mean. 
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Additionally, the occupancy of the MuRF1 promoter by MRFs was analyzed when myogenin or 
MyoD were overexpressed in the cell line. The qPCR analysis of cells overexpressing these 
MRFs demonstrated induced occupancy of the MuRF1 promoter region.  (Figure 21).  
 
Figure 21. MRF overexpression induces MuRF1 Ebox promoter occupancy. MuRF1 Ebox promoter was highly 
occupied by myogenin in cells overexpressing myogenin, and with MyoD in cells overexpressing MyoD. C2C12 
myoblast cells were transfected one day after plating with pcDNA3 expression plasmids for either myogenin or MyoD 
and harvested at day 2 post-plating (PD2). The myoblasts were maintained in standard culture media. ChIP was 
performed and DNA-protein complexes were pulled down with antibodies for myogenin (anti-myogenin) and MyoD 
(anti-MyoD). Each qPCR condition was run in triplicate and the error bars represent standard deviation (-/+ S.D.) of 
the mean. 
 
Ectopic expression of MuRF1 reverses MRF occupancy of the MuRF1 promoter region 
Overexpressing ectopic MyoD and myogenin seemed to show induced levels of amplification of 
the MuRF1 promoter. In order to assess the ability of MuRF1 to drive down myogenin and/or 
MyoD occupancy of the MuRF1 proximal promoter cells overexpressing myogenin or MyoD +/- 
MuRF1 were used for ChIP assays as described above. The qPCR analysis showed the 
previously observed induction in occupancy of the MuRF1 promoter by myogenin and MyoD. 
More importantly, the overexpression of MuRF1 concurrently with either myogenin or MyoD 
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resulted in MuRF1-mediated reversal of the MRF occupancy of the MuRF1 proximal promoter 
(Figure 22).  
  
Figure 22. MuRF1-mediated reversal of MRF-induced MuRF1 Ebox promoter occupancy.  MuRF1 Ebox 
promoter occupancy in cells overexpressing myogenin and MyoD was reversed when MuRF1 was overexpressed. 
C2C12 myoblast cells were transfected one day after plating with pcDNA3 expression plasmids for either MuRF1 +/- 
myogenin or MyoD and harvested at day 2 post-plating (PD2). The myoblasts were maintained in standard culture 
media. ChIP was performed and DNA-protein complexes were pulled down with antibodies for a) myogenin (anti-
myogenin) and b) MyoD (anti-MyoD).  Each qPCR condition was run in triplicate and the error bars represent 
standard deviation (-/+ S.D.) of the mean. 
 
Discussion 
MuRF1 has been widely accepted as a marker and key regulator of skeletal muscle atrophy; 
however, very few mechanistic targets have been identified to date. Previously, it was found that 
MuRF1 expression showed a significant upregulation under denervation conditions, but returned 
to baseline levels by 14 days post-denervation in wild-type (WT) animals, while the MuRF1 
locus (i.e. β-galactosidase) activity failed to return to baseline levels in MuRF1 knock-out (KO) 
animals. Furthermore, microarray analysis showed that myogenic regulatory factors such as 
myogenin and MyoD are significantly upregulated in response to denervation. These findings 
were among the first to suggest that MuRF1 may act as a transcriptional regulator in muscle 
atrophy. 
Previous unpublished data from our lab supports the role of MuRF1 as a transcriptional 
regulator. MuRF1 and MAFbx reporter plasmid activity was driven down by overexpressing 
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MuRF1, suggesting that MuRF1 can transcriptionally regulate itself, MAFbx and other muscle-
specific genes.  Furthermore, when MRFs were overexpressed they induced MuRF1 and MAFbx 
promoter activity, while MuRF1 and MRF co-overexpression reversed MRF induction of the 
MuRF1 and MAFbx promoters. This was the first study to suggest that MuRF1 may modulate 
MRF transcriptional activity. This thesis served to characterize this previously unidentified role 
of MuRF1 as a transcriptional regulator in skeletal muscle through its regulation of myogenin 
and MyoD. These findings together support the hypothesis that MuRF1 is likely acting through 
the transcriptional model to alter the expression of atrophy related genes in muscle cells. 
  
MyoD and myogenin show sequential expression in differentiating myoblasts 
As mentioned, the MyoD-family of transcription factors controls muscle cell determination and 
differentiation [28]. MyoD has a previously determined role in myogenic determination and 
myogenin promotes the commitment of myoblasts to terminal differentiation [18]. Myoblast 
fusion is a highly-regulated process and previous studies suggest that MyoD acts as a “pioneer” 
to initiate a cascade of events triggering the expression of muscle-specific genes. It has been 
hypothesized that these events then allow the sequential binding and activity of myogenin. 
Myogenin and MyoD expression in C2C12 muscle myoblasts showed that MyoD increased in 
expression early in proliferation and decreased by day 5 of differentiation (Figure 15). Myogenin 
expression increases early in differentiation, only after there is an increase in MyoD expression 
(Figure 14). This is consistent with a published study showing a similar trend of myogenin and 
MyoD expression in C2C12 cell lines over a time course of differentiation [18]. These data 
confirmed and supported the characterization of the sequential expression of myogenin and 
MyoD in muscle cell differentiation.  
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MuRF1 and the catalytically dead MuRF1 RING mutant regulate myogenin but not MyoD 
protein expression                                                                                  
Previous unpublished data from reporter assays performed in our lab showed that MuRF1 had an 
ability to coordinate with myogenin and MyoD to regulate promoter activity of muscle-specific 
genes (Figure 10, Figure 11). Western blot analysis was performed on cells ectopically 
overexpressing myogenin and MyoD with and without overexpression of MuRF1 and the 
MuRF1-RING mutant. Ectopic expression of MuRF1 blunted the expression of myogenin. 
Additionally, the catalytically MuRF1-RING mutant, incapable of ubiquitinating proteins, was 
still able to blunt levels of myogenin (Figure 16).  These data suggest that MuRF1 can 
effectively modulate levels of myogenin, even without a fully functional catalytic domain. These 
data were the first to suggest that this regulation was not occurring through catalytic activity of 
the RING Finger domain. Interestingly, when Western blot analysis was performed and MyoD 
was isolated there was no difference seen in MyoD protein expression upon over-expression of 
MuRF1 or the MuRF1-RING mutant (Figure 17).  These findings support that MuRF1 is able to 
regulate the levels of myogenin, but not MyoD, and that this regulation is through a previously 
uncharacterized function by MuRF1. 
In previous literature, the E3 ligase MAFbx has been characterized to be an F-box protein with a 
role in the ubiquitination of myogenin, which has a MAFbx- recognition motif [29]. 
Additionally, MAFbx has been characterized to regulate the expression of MyoD by means of 
ubiquitination [30]. While we know that MAFbx can regulate the expression of both myogenin 
and MyoD, this ability of MuRF1 to do so has not been previously investigated to our 
knowledge. Again, these data show that MuRF1 can alter the expression of myogenin but not 
MyoD. Previous research has suggested that even though MuRF1 and MAFbx are both 
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upregulated in atrophy conditions, the targets of these two E3 ligases may be completely 
different [31]. Thus, it is not entirely surprising we see effects on myogenin but not MyoD. 
 
Inhibition of the 26S proteasome does not rescue myogenin protein levels in response to   
MuRF1 overexpression 
To further investigate the mechanism by which MuRF1 is regulating myogenin, the role of the 
26S proteasome was also investigated. Western blotting analysis was performed after treating 
cells with MG132, a general 26S proteasome inhibitor. The results showed that while there was 
an increase in the amount of myogenin recovered, proteasome inhibition was not enough to fully 
rescue myogenin protein levels, as myogenin expression was still blunted when MuRF1 was 
overexpressed in the cells (Figure 18).  This further confirmed that MuRF1 is not regulating 
myogenin through the proteasome system. While we found that MuRF1 was not regulating 
myogenin through ubiquitination, these data further elucidate that the hypothesized proteasome 
model of MRF regulation is invalid. While it is widely accepted that MuRF1 polyubiquitinates 
proteins for degradation through the UPS, these data suggest that MuRF1 may be involved in a 
feedback mechanism responsible for transcriptionally regulating atrophy-related genes through 
the transcriptional regulation of myogenic regulatory factors such as myogenin.  
No effect was seen on MyoD when the catalytic function of the MuRF1 RING domain was 
destroyed (Figure 17) or when the proteasome was inactivated (Figure 19). Conversely, MuRF1 
was able to down-regulate myogenin levels in both of these cases. Previous literature has 
established MyoD as a transcriptional regulator of myogenin [38], therefore we have reason to 
believe that MuRF1 may be acting to regulate myogenin by negatively regulating MyoD, thus 
resulting in a down-regulating the expression levels of myogenin.  
 
32 
 
 
Endogenous myogenin and MyoD associate with the MuRF1 conserved Ebox sequence 
Previous data suggests that MuRF1 regulates myogenin and/or MyoD to suppress MuRF1 and 
MAFbx reporter gene activity. To further investigate the mechanistic coordination of MuRF1 
with the MRFs, chromatin immunoprecipitation (ChIP) was implemented to examine if the 
MuRF1 promoter was being occupied by endogenous levels of either myogenin or MyoD. The 
qPCR analysis using primers spanning the MuRF1 Ebox enhancer region suggested that MuRF1 
was occupied the most by MyoD early in proliferation and myogenin early in differentiation 
(Figure 20).  
 
These results suggest that myogenin and MyoD sequentially associate with Ebox enhancer 
sequences in the promoter region of MuRF1 in mouse myoblasts, with MyoD seemingly 
occupying the MuRF1 promoter early in proliferation and myogenin early in differentiation. This 
is not unexpected, as we know that MyoD is expressed at higher levels earlier in differentiation, 
while myogenin is expressed in higher levels later in differentiation.  These findings support 
expression patterns that were observed with western blot analysis of endogenous MyoD and 
myogenin expression in the cell line. This may explain the possible pattern of the induced 
association between these MRFs and the MuRF1 Ebox region, especially if MuRF1 is being 
induced to regulate muscle-specific genes downstream in the atrophy cascade. Previous literature 
has confirmed that histone deacetylases such as Hdac4 upregulate the expression of MRFs which 
in turn upregulate MuRF1 and MAFbx, but a direct mechanism for the upregulation of MuRF1 
has not been identified to our knowledge [21]. While previous unpublished data has 
characterized that atrogenes containing these conserved Ebox regions in the promoter can be 
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regulated by MRF overexpression, this thesis provides the first investigation of the mechanism 
by which MRFs directly bind to transcriptionally regulate the activity of these E3 ligases.  
 
Co-overexpressing MRFs with MuRF1 shows MuRF1-mediated reversal of MRF-induced 
occupancy of the MuRF1 promoter 
Myogenin and MyoD were overexpressed in C2C12 cells and ChIP was performed to investigate 
the effect of overexpression on MRF occupancy of the MuRF1 promoter in atrophy-like 
conditions (i.e. induced MRF levels). It was predicted that high levels of MuRF1 promoter 
occupancy when myogenin and MyoD were overexpressed and pulled down, as overexpression 
of myogenin and MyoD in reporter assays induced reporter activity of MuRF1 and MAFbx. The 
results confirmed that occupancy of the MuRF1promoter was induced when overexpressing 
MRFs (Figure 21).  
In previous research co-overexpression of MuRF1 with MRFs drove down the MRF-mediated 
induction of the MuRF1 promoter in reporter assays. Therefore, it was expected that MuRF1 
overexpression would be able to drive down the amplification of MuRF1 promoter association of 
both myogenin and MyoD. The results of this experiment confirmed that co-overexpressing 
MuRF1 with MRFs resulted in a MuRF1-mediated reversal of myogenin and MyoD occupancy 
with the MuRF1 promoter (Figure 22). Additionally, it seems that there is more occupancy of the 
MuRF1 promoter by MyoD, which further supports our hypothesis that MuRF1 is regulating 
myogenin levels through somehow negatively regulating MyoD.  
These data also signified that there is a possible feedback loop occurring in which MuRF1 is 
regulating its own transcriptional regulation. This is supported by the microarray analysis 
showing that MuRF1 promoter activity did not return to baseline levels in MuRF1 KO mice at 14 
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days, which was the first hint at MuRF1 acting as a transcriptional regulator of itself [13].  It also 
builds on preliminary research showing that overexpression of MuRF1 down-regulated MuRF1 
reporter gene activity. These data strongly suggest that MuRF1 can, in fact, regulate its own 
transcriptional activity. It is apparent that myogenin and MyoD are associating at the Ebox 
region of the MuRF1 promoter. Additionally, when MuRF1 was overexpressed in C2C12 cells 
there were lower levels of MRF occupancy at the MuRF1 promoter. This is the first study that 
hints at a mechanism by which MuRF1 acts as a transcriptional regulator indirectly through the 
regulation of myogenin, possibly by negatively regulating MyoD.  
Transcriptional regulation of atrophy-related genes may be regulated by a potentially intricate set 
of feedback mechanisms between E3 ligases and MRFs.  For example, myogenin and MyoD are 
upregulated in response to atrophy [36] and we know that MyoD must be present to activate 
myogenin recruitment [37]. In turn, myogenin acts  as a transcriptional regulator of E3 ligases 
such as MuRF1 and MAFbx [38]. The data in this thesis supports the characterization of MuRF1 
as a transcriptional regulator of not only itself, but other atrophy-related genes such as myogenin 
and MyoD.  Thus, it is reasonable to propose that MuRF1 participates in a feedback mechanism 
that regulates its own expression and regulates the binding of myogenin and MyoD to Ebox 
enhancer regions, as they also play a key in the transcriptional regulation of muscle specific 
genes.  
While this thesis confirms that MuRF1 is not regulating MRFs via the UPS or through the 
catalytic activity of the MuRF1 RING Finger domain, MuRF1 may be responsible in regulating a 
change in association and/or recruitment of the MRFs and/or their E protein binding partners to 
E-box elements within target gene regulatory regions. It is also possible that MyoD1 and 
myogenin may recruit MuRF1 to the promoters of target genes and allow for modification of 
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other participants in the transcriptional regulatory process.  MuRF1 could also be involved in 
targeting recruitment of additional transcription factors to the promoters of atrophy-induced 
genes, or interact with or recruit additional proteins which themselves associate with the 
promoters of muscle-specific genes. 
High levels of expression of MuRF1 may play an additional role in preventing these MRFs from 
sitting on the Ebox sequence of promoter regions. It is thought that the primary interaction of the 
MRFs is to dimerize before they associate with a promoter region [39]. These transcription 
factors must either homodimerize or heterodimerize with factors such as E proteins to form a 
functional dimer that can sit down on the consensus E-box sequences [39, 40]. MuRF1 may have 
a role in regulating MyoD or the binding partners of MyoD, thus preventing them from 
dimerizing with their appropriate binding partners to effectively transcriptionally regulate 
myogenin. This may ultimately sequester these MRFs from effectively sitting down on 
conserved Ebox promoter regions. 
We propose a novel function of MuRF1 in targeting downstream atrogenes through 
transcriptional regulation, mainly through the negative regulation of myogenin and MyoD at the 
conserved Ebox sequences in the promoter regions of muscle-specific genes.  Further research on 
how MuRF1 is mechanistically modulating MRFs to ultimately transcriptionally regulate 
atrogenes will need be conducted, but this study serves as the first evidence of the coordination 
of MuRF1 and MRFs in the transcriptional regulation of muscle specific genes during skeletal 
muscle atrophy. 
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Conclusions  
In summary, the data herein elucidates a previously uncharacterized function for MuRF1 as a 
transcriptional regulator of atrogenes through the transcriptional regulation of the myogenic 
regulatory factors, myogenin and MyoD. MuRF1 is largely recognized in literature as an E3 
ubiquitin ligase that is expressed at high levels under virtually all atrophy conditions; however, 
these data suggest that MuRF1 is also working outside of the ubiquitin proteasome system to 
transcriptionally regulate itself and other muscle specific genes through a feedback loop that 
controls MRF-mediated regulation of gene expression in muscle atrophy.  
Previously, it was shown that MuRF1 can regulate the promoter activity of itself by mediating 
the activity of MyoD and myogenin. We have now determined that MuRF1 modulates myogenin 
and MyoD occupation of the conserved Ebox sequence found in the promoter region of MuRF1. 
Interestingly, when MuRF1 was overexpressed concurrently with myogenin or MyoD we saw a 
decrease in the occupancy of the MRFs at the Ebox promoter region of MuRF1.  Western blot 
analysis also indicated that MuRF1 regulates myogenin but not MyoD, suggesting that it has 
specific downstream targets that differ from other E3 ligases such as MAFbx. Furthermore, 
MuRF1 was still capable of decreasing the amount of myogenin protein expression without both 
the catalytic RING domain and without the function of the 26S proteasome. This refutes that 
MuRF1 is regulating the MRFs through its previously characterized function of an E3 ligase 
working through the UPS (Figure 12) and supports our previously mentioned transcription model 
(Figure 13); MuRF1 may be acting as a transcriptional regulator of myogenin and other atrophy-
related genes, possibly via the negative regulation of MyoD. 
Additional research is still needed to further characterize the exact mechanism by which MuRF1 
is acting as a transcriptional regulator. The involvement of E proteins, which are the ubiquitously 
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expressed binding partners of myogenin and MyoD, should also be investigated to better 
understand how MuRF1 can modulate the MRFs. MRF occupancy of the MuRF1 promoter 
should also be evaluated in response to ectopic expression of MuRF1 mutants, as well as siRNA 
knockdown of MuRF1. The preferential regulation of myogenin over MyoD should also be 
further investigated, as this could elucidate the function of MuRF1 in regulating transcriptional 
activity of atrophy-related genes. Finally, MuRF1 might also be investigated beyond its 
capabilities as a transcriptional regulator; the nature of skeletal muscle atrophy is intricate and 
regulation occurs on many levels, therefore the analysis of MuRF1 post-transcriptionally would 
also likely yield pertinent information regarding the molecular mechanisms of skeletal muscle 
atrophy. 
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Supplemental Figures  
  
 
 
 
 
 
  
Figure S1. Protein expression profile of myogenin (~34 kDa) in C2C12 mouse myoblasts is decreased upon 
overexpression of MuRF1 or MuRF1-RING mutant. C2C12 myoblast cells were transfected with control expression 
plasmid alone (-/-) or expression plasmids for either MuRF1 or MuRF1 RING mutant and harvested at day 2 (D2) and 
day 9 (D9) after the switch to differentiation media (2% serum). Western blotting was performed using 150µg of total 
protein and probed using an antibody against myogenin. 
 
 
 
 
 
 
 
 
Figure S2. Protein expression profile of MyoD (~45 kDa) in C2C12 mouse myoblasts remains unaltered upon 
overexpression of MuRF1 or MuRF1-RING mutant. C2C12 myoblast cells were transfected with control 
expression plasmid alone (-/-) or expression plasmids for either MuRF1 or MuRF1 RING mutant and harvested at day 
2 (D2) and day 9 (D9) after the switch to differentiation media (2% serum). Western blotting was performed using 
150µg of total protein and probed using an antibody against MyoD.  
 
 
 
Figure S3.  Protein expression profile of myogenin (~34kDa) and MyoD (~45 kDa) in C2C12 mouse myoblasts 
treated with MG132 (12.5µg/µL) and ectopically expressing MuRF1 or the catalytically dead MuRF1 RING 
mutant. MuRF1-mediated repression of myogenin expression levels are partially reversed in the presence of MG132 
but are not completely rescued from the blunting effect by ectopic MuRF1 or MuRF1 RING mutant. MyoD expression 
levels are partially reversed in the presence of MG132, but no differences are seen upon expression of ectopic MuRF1 
or MuRF1 RING mutant. Myoblasts were transfected with control expression plasmid alone (-/-) or an expression 
plasmid for MuRF1 and harvested at day 2 (D2) and day 9 (D9) after the switch to differentiation media (2% serum). 
Western blotting was performed using 150µg of total protein probed using an antibody against myogenin or MyoD.  
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